FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) stock fell 6% after the medical device maker cut its Q4 sales and full-year EPS guidance due to ongoing disruptions from an August cyberattack. The company estimated the eight-day cyberattack cost it 300 basis points in sales growth and $0.07 in adjusted EPS. Management expects a slow recovery with 2027 projected as the trough year, though the stock now trades at a relatively low 13x forward earnings multiple.

Abbott Receives FDA Approval For First And Only Device In The U.S. To Treat Leaks After Heart Valve Replacement Without Additional Surgery

Abbott's Role in the Growing Global Leadless Pacemaker Market

Abbott continues to address clinical needs in the leadless pacemaker market with its AVEIR DR system as the industry projects significant growth through 2036.

This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.

Beta Bionics Reports Third Quarter 2026 Financial Results and Updates Guidance

Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.